Morphic Holding Inc CEO Praveen Tipirneni Sells 13,923 Shares
On January 16, 2024, CEO of Morphic Holding Inc (NASDAQ:MORF), Praveen Tipirneni, sold 13,923 shares of the company, according to a recent SEC Filing. Morphic Holding Inc is a biopharmaceutical company focused on the discovery and development of oral small-molecule integrin therapeutics for serious chronic diseases, including fibrosis, cancer, and autoimmune conditions.
Over the past year, the insider has sold a total of 54,330 shares and has not made any purchases of the company's stock.
The insider transaction history at Morphic Holding Inc reveals a pattern of insider activity. In the past year, there have been 3 insider buys and 23 insider sells.
On the date of the insider's recent transaction, shares of Morphic Holding Inc were trading at $27.49, resulting in a market cap of $1.351 billion.
The stock's price-to-GF-Value ratio stands at 59.76, with a GF Value of $0.46, indicating that Morphic Holding Inc is significantly overvalued according to GuruFocus' valuation metrics.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
